COMy 2019 | LYRA findings: frontline CyBorD-Dara for myeloma

Michael O’Dwyer

Michael O’Dwyer, MD, PhD, from the National University of Ireland, Galway, Ireland, discusses the results from the LYRA study (NCT02951819), where the anti-CD-38 monoclonal antibody daratumumab was used in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) as a front-line therapy for multiple myeloma. Prof. O’Dwyer highlights the very good partial response rates seen, as well as the high rate of MRD negativity. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

Share this video